Skip to main content
Home

Main navigation

  • Company
    • Company profile
    • Leadership team
    • Scientific Advisory Board
    • Board of Directors
  • R&D Programs
    • Pipeline overview
    • DIACC1010
    • DIACC2010/DIACC2020
    • DIACC3010
  • Partnering
  • Media
    • Media hub
    • All press releases
    • All events
    • Media center
  • Careers
  • Contact
  • Search
  • en
  • fr
  1. Home
  2. Media

All press releases

  • Diaccurate welcomes to its Board of Directors Prof. Karine Lacombe, internationally renowned infectious disease specialist and Dr. Catherine George, expert in early drug development

    June 24, 2022
  • Diaccurate appoints Laurence Riot Lamotte as Chief Financial Officer

    February 8, 2022
  • Diaccurate Acquires Clinical Stage Sole-in-Class Targeted Cancer Therapy from Merck KGaA, Darmstadt, Germany

    September 8, 2021
  • Diaccurate introduces its world-leading Scientific Advisory Board

    July 8, 2021
  • Diaccurate acquires Biokinesis to create a sole-in-class biotech player in oncology and immunotherapy

    January 12, 2021
  • World Premiere: Diaccurate reveals the mechanism of immune disablement in HIV infection

    March 3, 2020
  • Diaccurate appoints 4 world-class experts to head its scientific board

    June 24, 2019

Location

Headquarters: 104 Bd de Sébastopol, 75003 Paris

Lab: 60 avenue André Roussin, 13016 Marseille

  33 (0)1 78 96 41 70

Stay in touch

Subscribe to our newsletter

Contact us

Follow us

   

Footer

  • Legal info
  • Privacy notice
  • Cookies notice